Remove 2026 Remove Networking Remove Patients
article thumbnail

Sandoz to build biologics plant in Slovenia

European Pharmaceutical Review

Signing of the MOU “sets up Sandoz to expand patients’ access to the large number of biologics losing patent protection over the next few years,” commented Dominic Wake, Head of Market Access and Corporate Affairs at Sandoz. Full operations is provisionally planned for late 2026.

article thumbnail

EU regulators release new workplan for accelerating clinical research

European Pharmaceutical Review

The 2022-2026 workplan of the initiative Accelerating Clinical Trials in the EU ( ACT EU ) has been published by the European Commission (EC), Heads of Medicines Agencies (HMA) and European Medicines Agency (EMA). implementing the CTR – focus on CTIS and CTR training activities and trouble-shooting any issues encountered by trial sponsors.

Medicine 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sandoz plans new biologics production plant construction in Slovenia

Pharmaceutical Technology

It represents one of the largest-ever global private-sector investments in the country and strengthens the company’s Europe-wide production network. Sandoz CEO Richard Saynor said: “Biosimilar medicines increase access to cutting-edge biologic therapies for the patients who need them most. “At

article thumbnail

U.S. market access landscape: A push for control is erasing the boundary between payers and providers in U.S. healthcare

Clarivate

Health systems will buy or establish an insurance plan to serve as an extension of their continuum of care, a means of directing referral streams to increase revenue and securing control over clinical and formulary decisions for patients.

article thumbnail

The post-Covid New Normal: a golden opportunity for the NHS?

pharmaphorum

Notable highlights include the central role the UK has played in the field of genomics, with over 500 thousand patients now in the biobank, and the recent RECOVERY trial – the world’s largest clinical trial into treatments for Covid-19, with more than 40,000 participants across 185 trial sites in the UK. Accelerating access for patients.

article thumbnail

New €300m Angelini Ventures fund combines venture creation and direct investments to pave the way for healthcare transformation

pharmaphorum

As many strive to bring about transformation in healthcare, Angelini Ventures takes a new approach to investments in digital health and life sciences companies that drive healthcare innovation and improve patient experiences. Serenis provides a unique platform that matches patients in need with certified therapists.

article thumbnail

A Look Into Telehealth in 2021 and Beyond

Pharma Marketing Network

Billion by 2026 with a CAGR of 37.2% The COVID-19 pandemic seriously accelerated the adoption and implementation of telehealth services, like remote patient monitoring and out-of-office “visits” – a trend that was already on the incline. And what are the implications to patients and providers? over the Forecast Period.”.